Patents Assigned to British Biotech Pharmaceuticals Limited
-
Patent number: 5696082Abstract: Compounds of general formula (I) wherein X is --CONHOH or --CO.sub.2 H, principally characterised by the presence in substituent R.sub.3 and/or R.sub.4 of a group of formula (II) are inhibitors of matrix metalloproteinases and inhibitors of the production of turnout necrosis factor.Type: GrantFiled: May 28, 1996Date of Patent: December 9, 1997Assignee: British Biotech Pharmaceuticals LimitedInventors: Michael John Crimmin, Andrew Paul Ayscough, Raymond Paul Beckett
-
Patent number: 5691382Abstract: The present invention is directed to the method of inhibiting the release of tumor necrosis factor (TNF) in a condition mediated by TNF by administration of certain hydroxamic add derivatives, also known as matrix metalloproteinase inhibitors, and thus the method of this invention is useful in the management of diseases or conditions mediated by TNF.Type: GrantFiled: May 12, 1995Date of Patent: November 25, 1997Assignee: British Biotech Pharmaceuticals LimitedInventors: Michael John Crimmin, William Alan Galloway, Andrew John Hubert Gearing
-
Patent number: 5645833Abstract: Serine proteases of the chymotrypsin superfamily are modified so that they exhibit resistance to serine protease inhibitors. If such modified serine proteases have fibrinolytic, thrombolytic, antithrombotic or prothrombotic properties, they are useful in the treatment of blood clotting diseases or conditions.Type: GrantFiled: February 3, 1995Date of Patent: July 8, 1997Assignee: British Biotech Pharmaceuticals LimitedInventors: Keith Martyn Dawson, Richard James Gilbert
-
Patent number: 5643964Abstract: Compounds of Formula (I) wherein R.sub.2 represents a group R.sub.6 --A-- wherein A represents a divalent straight or branched, saturated or unsaturated hydrocarbon chain of up to 6 C atoms which may be interrupted by an O or S atom, and R.sub.6 represents hydrogen or an optionally substituted phenyl, cycloalkyl or cycloalkenyl group; R.sub.3 represents the characterizing side chain of a natural alpha amino acid other than proline, and in which any polar substituents are optionally protected; R.sub.4 represents hydrogen or methyl; R.sub.5 represents hydrogen, C.sub.1 -C.sub.6 alkyl or a group D-(C.sub.1 -C.sub.6 alkyl) wherein D represents hydroxy, (C.sub.1 -C.sub.6)alkoxy, (C.sub.1 -C.sub.6)alkylthio, acylamino, optionally substituted phenyl, or a heterocyclic group, NH.sub.2, or a mono- or di-(C.sub.1 -C.sub.6 alkyl) amine or a heterocyclic group; or R.sub.3 and R.sub.Type: GrantFiled: January 23, 1995Date of Patent: July 1, 1997Assignee: British Biotech Pharmaceuticals LimitedInventors: Jonathan Philip Dickens, Michael John Crimmin, Raymond Paul Beckett
-
Patent number: 5563151Abstract: Compounds of general formula I: ##STR1## wherein W represents imidazo [4,5-c]pyridin-1-yl, imidazo [4,5-c]pyridin-3-yl and imidazo [4,5-c]pyridin-5-yl optionally substituted with one or more --C.sub.1 -C.sub.6 alkyl substituents; Z represents a) a divalent alkanediyl, alkenediyl or alkynediyl group; b) a --(CH.sub.2).sub.q U(CH.sub.2).sub.r -- group, optionally substituted, wherein q is an integer from 0-3, r is an integer from 0-3 and U is --O-- or --S--; Q represents a carbonyl, thiocarbonyl or sulphonyl group; B represents a) a --VR.sup.8 group wherein V is --C(.dbd.O)O-- or --CH.sub.2 O--; are antagonists of platelet activating factor (PAF).Type: GrantFiled: September 1, 1994Date of Patent: October 8, 1996Assignee: British Biotech Pharmaceuticals limitedInventors: Stephen A. Bowles, Andrew Miller, Mark Whittaker
-
Patent number: 5516783Abstract: The present invention is directed to compounds of general formula I as well their pharmaceutically and veterinarily acceptable acid addition salts or hydrates thereof. The present invention is further directed to pharmaceutical and veterinary compositions containing the compounds of general formula I. The present compounds of general formula I are antagonist of platelet activating factor (PAF). Accordingly, the present invention is also directed to methods for preventing, treating or ameliorating in human or mammalian animals, various diseases or physiological conditions mediated by PAF.Type: GrantFiled: October 27, 1994Date of Patent: May 14, 1996Assignee: British Biotech Pharmaceuticals LimitedInventors: Mark Whittaker, Stephen A. Bowles, Andrew Miller
-
Patent number: 5514677Abstract: Compounds of general formula I: ##STR1## wherein: A represents the group --NH.sub.2, a substituted acyclic amine or a heterocyclic base;have collagenase inhibition activity and are useful in the management of disease involving tissue degradation and/or the promotion of wound healing. Diseases involving tissue degradation include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption diseases and tumour invasion.Type: GrantFiled: April 18, 1994Date of Patent: May 7, 1996Assignee: British Biotech Pharmaceuticals LimitedInventors: Alan H. Davidson, Jonathan P. Dickens, Michael J. Crimmin
-
Patent number: 5512545Abstract: PDGF-B analogues are prepared in which an amino acid residue at a protease site is replaced with the corresponding amino acid residue from PDGF-A. The polypeptide is obtained at yields which are five to ten times greater than that for naturally occurring PDGF-B and retains the biological activity of the natural polypeptide.Type: GrantFiled: August 31, 1993Date of Patent: April 30, 1996Assignees: British Biotech Pharmaceuticals Limited, Pfizer LimitedInventors: David Brown, Richard M. Edwards, Stewart Craig, Anne L. Cook, John M. Clements
-
Patent number: 5463024Abstract: Fusion proteins comprise a first amino acid sequence and a second amino acid sequence. The first amino acid sequence is derived from a retrotransposon or an RNA retrovirus and confers on the fusion protein the ability to assemble into particles; an example is the product of the TYA gene of the yeast retrotransposon Ty. The second amino acid sequence is biologically active; for example it may be antigenic. So particles formed of the fusion proteins may be useful in vaccines or in diagnostic or purification applications.Type: GrantFiled: September 1, 1993Date of Patent: October 31, 1995Assignee: British Biotech Pharmaceuticals LimitedInventors: Alan J. Kingsman, Susan M. Kingsman, Sally E. Adams, Elizabeth J. C. Mellor, Michael H. Malim
-
Patent number: 5453438Abstract: Compounds of general formula I: ##STR1## are presented that have collagenase inhibition activity and are useful in the management of disease involving the tissue degradation and the promotion of would healing. Diseases involving tissue degradation include arthropathy (particularly rheumatoid arthritis), inflammation, dermatological diseases, bone resorption diseases and tumor invasion.Type: GrantFiled: January 16, 1992Date of Patent: September 26, 1995Assignee: British Biotech Pharmaceuticals LimitedInventors: Colin Campion, Alan H. Davidson, Jonathan P. Dickens, Michael J. Crimmin
-
Patent number: 5451676Abstract: Compounds of the general formula I; ##STR1## wherein: A.sup.1 is .dbd.N--, .dbd.CH-- or .dbd.CR.sup.1 --;A.sup.2 is --N.dbd., --CH.dbd. or --CR.sup.2 .dbd.;provided that, when one of A.sup.1 and A.sup.2 is a nitrogen atom, the other of A.sup.1 and A.sup.2 is other than a nitrogen atom;wherein the remainder of the variables are defined in the specification;and their pharmaceutically and veterinarily acceptable acid addition salts and hydrates are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.Type: GrantFiled: November 1, 1993Date of Patent: September 19, 1995Assignee: British Biotech Pharmaceuticals LimitedInventors: Mark Whittaker, Andrew Miller, Stephen A. Bowles
-
Patent number: 5446032Abstract: Compounds of formula I: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9, and B are variables. These compounds are antagonists of platelet activating factor (PAF) and as such are useful in the treatment or amelioration of various diseases or disorders mediated by PAF.Type: GrantFiled: February 28, 1994Date of Patent: August 29, 1995Assignee: British Biotech Pharmaceuticals LimitedInventors: Mark Whittaker, Andrew Miller
-
Patent number: 5428168Abstract: The invention encompasses compounds of general formula I: ##STR1## wherein W represents an imidazo[4,5-c]pyridyl group, optionally substituted with one or more substituents selected from C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halo, CF, and CN; and Z, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 are variables. These compounds are useful as antagonists of platelet activating factor.Type: GrantFiled: October 23, 1992Date of Patent: June 27, 1995Assignee: British Biotech Pharmaceuticals LimitedInventors: Mark Whittaker, Alan H. Davidson, Zoe M. Spavold, Stephen A. Bowles
-
Patent number: 5409937Abstract: The invention concerns compounds of the formula I: ##STR1## wherein the variables are described in the specification which are antagonists of platelet activity factor.Type: GrantFiled: April 18, 1994Date of Patent: April 25, 1995Assignee: British Biotech Pharmaceuticals LimitedInventor: Mark Whittaker